Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 4/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16772406 | 0.92 | RAB9A (0.44) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL8582883 | 0.82 | PTGS2 (0.55) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL19789802 | 0.78 | MAOB (0.47) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL28731104 | 0.74 | — | — | |
| SCHEMBL7793551 | 0.72 | MAOB (0.60) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL7793547 | 0.72 | MAOB (0.60) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL16755697 | 0.72 | MAOB (0.42) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL806603 | 0.72 | TRPA1 (0.48) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL3859044 | 0.70 | MAOB (0.44) | PTGS2MAOBRAB9AKDM4EMAPT | |
| SCHEMBL18417133 | 0.69 | TRPA1 (0.57) | RAB9AKDM4EMAPTNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110664816-A | SECA inhibitors and methods of making and using the same | 佐治亚州立大学研究基金会公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3409666-A2 | SECA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | Georgia State University Research Foundation, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180222880-A1 | SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-08-09 | — | — | US | disclosed |
| US-20180222880-A1 | SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-08-09 | — | — | US | disclosed |
| US-9957247-B2 | SecA inhibitors and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957247-B2 | SecA inhibitors and methods of making and using thereof | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| EP-2861580-B1 | SECA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2861580-B1 | SECA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | UNIV GEORGIA STATE RES FOUND (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20150152077-A1 | SecA Inhibitors and Methods of Making and Using Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
| US-20150152077-A1 | SecA Inhibitors and Methods of Making and Using Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222880-A1 | SecA INHIBITORS AND METHODS OF MAKING AND USING THEREOF | SEC61B, SEC61A1, SEC23A | PTGS2 3140/4885MAOB 2736/4885RAB9A 492/4885 |
| US-20150152077-A1 | SecA Inhibitors and Methods of Making and Using Thereof | SEC61B, SEC61A1, SEC23A | PTGS2 3140/4885MAOB 2736/4885RAB9A 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.